Jörn Güldenhaupt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jörn Güldenhaupt has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Carsten Kötting
Center for Protein Diagnostics (PRODI), Biospectroscopy, Ruhr University Bochum, Bochum, Germany
8 shared publications - Klaus Gerwert
Ruhr University Bochum
7 shared publications Jonas Schartner
3 shared publications- Adrian Höveler
Ruhr University Bochum
2 shared publications - Marta Amaral
Molecular Interactions and Biophysics Merck KGaA Frankfurter Straße 250 64293 Darmstadt Deutschland
2 shared publications - Marvin Mann
Center for Protein Diagnostics (PRODI)
2 shared publications
Latest Publications
- Open Access
- 12 January 2026
- Published by American Chemical Society (ACS) in ChemRxiv
A Reversible ATR-FTIR Biosensor with Single Residue Sensitivity
Infrared spectroscopy provides label-free access to protein structure information with high sensitivity. Challenges in infrared spectroscopy include artifacts arising from temperature changes, baseline drifts and the strong water absorption, especially in difference spectroscopy, where signals are orders of magnitude smaller than the total absorbance. Previously, we introduced an ATR-based immuno-infrared sensor (iRS) based on sophisticated surface chemistry. This provides a stable platform for covalent protein immobilization and allows its application with body fluids such as cerebrospinal fluid or blood without unspecific background. It detects misfolding of small amounts of antigen (Abeta or alpha-synuclein) by binding to an antibody or antibody fragment, which allows for the diagnosis of various neurodegenerative diseases. Here, we extend this platform by introducing reversible binding via the NColE7/Im7 pair. Im7-tagged proteins are captured with sub-picomolar affinity and quantitatively released under mild conditions (high salt or low pH), allowing repeated capture-regeneration cycles with continuous spectral monitoring of the Im7 fusion protein. Using an Im7-antibody Fab fusion protein, we present a reusable immune-IR sensor that enables multiple measurements on the same surface. For example, different antibodies can be used for differential screening. Using alternating Im7 protein attachments to the internal reflection element, we further compare Im7 single point mutants to wild-type Im7 to resolve infrared signatures of specific amino acid substitutions. Difference spectra reveal the distinct tyrosine absorption associated with either the introduction or removal of a single tyrosine residue, providing the first proof-of-concept for difference spectroscopy with single-residue sensitivity based on complete protein exchange.
- 12 January 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessA Reversible ATR-FTIR Biosensor with Single Residue Sensitivity
Infrared spectroscopy provides label-free access to protein structure information with high sensitivity. Challenges in infrared spectroscopy include artifacts arising from temperature changes, baseline drifts and the strong water absorption, especially in difference spectroscopy, where signals are orders of magnitude smaller than the total absorbance. Previously, we introduced an ATR-based immuno-infrared sensor (iRS) based on sophisticated surface chemistry. This provides a stable platform for covalent protein immobilization and allows its application with body fluids such as cerebrospinal fluid or blood without unspecific background. It detects misfolding of small amounts of antigen (Abeta or alpha-synuclein) by binding to an antibody or antibody fragment, which allows for the diagnosis of various neurodegenerative diseases. Here, we extend this platform by introducing reversible binding via the NColE7/Im7 pair. Im7-tagged proteins are captured with sub-picomolar affinity and quantitatively released under mild conditions (high salt or low pH), allowing repeated capture-regeneration cycles with continuous spectral monitoring of the Im7 fusion protein. Using an Im7-antibody Fab fusion protein, we present a reusable immune-IR sensor that enables multiple measurements on the same surface. For example, different antibodies can be used for differential screening. Using alternating Im7 protein attachments to the internal reflection element, we further compare Im7 single point mutants to wild-type Im7 to resolve infrared signatures of specific amino acid substitutions. Difference spectra reveal the distinct tyrosine absorption associated with either the introduction or removal of a single tyrosine residue, providing the first proof-of-concept for difference spectroscopy with single-residue sensitivity based on complete protein exchange.
- Open Access
Replacement of a single residue in an antibody completely abolishes cognate antigen binding, as predicted by theoretical methods
Structural insights into the interaction between antibodies and antigens at the atomic level are pivotal for understanding the molecular mechanisms of antigen binding. Despite the availability of structural models generated by recent artificial intelligence advancements, computational predictions require experimental validation to confirm their accuracy. Here, we demonstrate a novel approach that combines computational protein modeling with spectroscopic experiments to validate antibody-antigen interactions. As a case example we use solanezumab, a monoclonal antibody that targets amyloid-beta (Aβ), whose misfolding is the main factor responsible for Alzheimer’s disease. For this antibody we predicted a single mutation, G95A HC , within the paratope of the heavy chain to disrupt antigen binding. This mutation, referred to as a “dead mutant”, was experimentally validated using an immuno-infrared biosensor (iRS). Our results confirmed that the mutation abolished antigen binding without affecting the native structure of the antibody. The use of dead mutants enables precise differentiation between specific and nonspecific binding, which is particularly important in medical diagnostics. We applied this approach to analyze the binding of solanezumab to synthetically produced Aβ variants and Aβ catched by the iRS functionalized surface from cerebrospinal fluid, showcasing its utility in Alzheimer’s disease diagnostics. These findings highlight the value of computational modeling and experimental validation in understanding antigen-antibody interactions, with significant implications for diagnostic and therapeutic applications.
Open AccessReplacement of a single residue in an antibody completely abolishes cognate antigen binding, as predicted by theoretical methods
Structural insights into the interaction between antibodies and antigens at the atomic level are pivotal for understanding the molecular mechanisms of antigen binding. Despite the availability of structural models generated by recent artificial intelligence advancements, computational predictions require experimental validation to confirm their accuracy. Here, we demonstrate a novel approach that combines computational protein modeling with spectroscopic experiments to validate antibody-antigen interactions. As a case example we use solanezumab, a monoclonal antibody that targets amyloid-beta (Aβ), whose misfolding is the main factor responsible for Alzheimer’s disease. For this antibody we predicted a single mutation, G95A HC , within the paratope of the heavy chain to disrupt antigen binding. This mutation, referred to as a “dead mutant”, was experimentally validated using an immuno-infrared biosensor (iRS). Our results confirmed that the mutation abolished antigen binding without affecting the native structure of the antibody. The use of dead mutants enables precise differentiation between specific and nonspecific binding, which is particularly important in medical diagnostics. We applied this approach to analyze the binding of solanezumab to synthetically produced Aβ variants and Aβ catched by the iRS functionalized surface from cerebrospinal fluid, showcasing its utility in Alzheimer’s disease diagnostics. These findings highlight the value of computational modeling and experimental validation in understanding antigen-antibody interactions, with significant implications for diagnostic and therapeutic applications.
- Open Access
Alpha-synuclein misfolding as a fluid biomarker for Parkinson’s disease and synucleinopathies measured with the iRS platform
Misfolding and aggregation of alpha-synuclein (αSyn) plays a key role in the pathophysiology of Parkinson’s disease (PD). It induces cellular and axonal damage already in the early stages of the disease. Despite considerable advances in PD diagnostics by αSyn seed-amplification assays (SAAs), an early and differential diagnosis of PD still represents a major challenge. Here, we extended the immuno-infrared sensor (iRS) platform technology from Alzheimer’s disease (AD), in which β-amyloid misfolding was monitored as a fluid biomarker towards αSyn misfolding in PD. Using the iRS platform technology, we analyzed cerebrospinal fluid (CSF) from two independent cohorts, a discovery and a validation cohort comprising clinically diagnosed PD (n=57), atypical Parkinsonian disorders with αSyn pathology (multiple system atrophy (MSA), n= 5) or Tau pathology (corticobasal degeneration (CBD), n=5, progressive supranuclear palsy (PSP) n=9), and further disease controls (frontotemporal dementia (FTD) n=7 and other, n=51). In the discovery cohort, an AUC of 0.90, 95 %-CL 0.85 – 0.96 is obtained for the differentiation of PD/MSA vs. all controls, and in the validation cohort, an AUC of 0.86, 95 %-CL 0.80 - 0.93, respectively. In the combined dataset, the αSyn misfolding classifies PD/MSA from controls with an AUC of 0.90 (n=134, 95 %-CL 0.85 - 0.96). Using two threshold values instead of one identified people in the continuum between clearly unaffected (low misfolding group) and affected by PD/MSA (high misfolding group) with an intermediate area in between. The controls versus PD/MSA in the low vs. high misfolding group were classified with 97% sensitivity and 92% specificity. The spectral data showed misfolding in CSF from an α-helical/random-coil secondary structure of αSyn in controls to β-sheet enriched secondary structures in PD and MSA patients. In subgroups, the iRS platform implied a potential for stratifying patients with overlapping clinical symptoms. With high accuracy, the iRS αSyn misfolding platform provides a novel diagnostic tool using body fluids for differential, biological classification of the αSyn associated disorders PD and MSA. The iRS platform, indicating directly and fast all αSyn conformers, is complementary to the αSyn SAAs, which also uses αSyn misfolding as a fluid biomarker. However, monomers amplify competent misfolded conformers in SAA over time. The iRS platform opens new avenues for the stratification of PD by a body-fluid analysis and follow-ups in the continuum of healthy to clinically impaired individuals.
Open AccessAlpha-synuclein misfolding as a fluid biomarker for Parkinson’s disease and synucleinopathies measured with the iRS platform
Misfolding and aggregation of alpha-synuclein (αSyn) plays a key role in the pathophysiology of Parkinson’s disease (PD). It induces cellular and axonal damage already in the early stages of the disease. Despite considerable advances in PD diagnostics by αSyn seed-amplification assays (SAAs), an early and differential diagnosis of PD still represents a major challenge. Here, we extended the immuno-infrared sensor (iRS) platform technology from Alzheimer’s disease (AD), in which β-amyloid misfolding was monitored as a fluid biomarker towards αSyn misfolding in PD. Using the iRS platform technology, we analyzed cerebrospinal fluid (CSF) from two independent cohorts, a discovery and a validation cohort comprising clinically diagnosed PD (n=57), atypical Parkinsonian disorders with αSyn pathology (multiple system atrophy (MSA), n= 5) or Tau pathology (corticobasal degeneration (CBD), n=5, progressive supranuclear palsy (PSP) n=9), and further disease controls (frontotemporal dementia (FTD) n=7 and other, n=51). In the discovery cohort, an AUC of 0.90, 95 %-CL 0.85 – 0.96 is obtained for the differentiation of PD/MSA vs. all controls, and in the validation cohort, an AUC of 0.86, 95 %-CL 0.80 - 0.93, respectively. In the combined dataset, the αSyn misfolding classifies PD/MSA from controls with an AUC of 0.90 (n=134, 95 %-CL 0.85 - 0.96). Using two threshold values instead of one identified people in the continuum between clearly unaffected (low misfolding group) and affected by PD/MSA (high misfolding group) with an intermediate area in between. The controls versus PD/MSA in the low vs. high misfolding group were classified with 97% sensitivity and 92% specificity. The spectral data showed misfolding in CSF from an α-helical/random-coil secondary structure of αSyn in controls to β-sheet enriched secondary structures in PD and MSA patients. In subgroups, the iRS platform implied a potential for stratifying patients with overlapping clinical symptoms. With high accuracy, the iRS αSyn misfolding platform provides a novel diagnostic tool using body fluids for differential, biological classification of the αSyn associated disorders PD and MSA. The iRS platform, indicating directly and fast all αSyn conformers, is complementary to the αSyn SAAs, which also uses αSyn misfolding as a fluid biomarker. However, monomers amplify competent misfolded conformers in SAA over time. The iRS platform opens new avenues for the stratification of PD by a body-fluid analysis and follow-ups in the continuum of healthy to clinically impaired individuals.
- Open Access
- 17 February 2021
- Published by American Chemical Society (ACS) in ChemRxiv
The Ras Dimer Structure
Oncogenic mutated Ras is a key player in cancer, but despite intense and expensive approaches its catalytic center seems undruggable. The Ras dimer interface is a possible alternative drug target. Dimerization at the membrane affects cell growth signal transduction. In vivo studies indicate that preventing dimerization of oncogenic mutated Ras inhibits uncontrolled cell growth. Conventional computational drug-screening approaches require a precise atomic dimer model as input to successfully access drug candidates. However, the proposed dimer structural models are controversial. Here, we provide a clear-cut experimentally validated N-Ras dimer structural model. We incorporated unnatural amino acids into Ras to enable the binding of labels at multiple positions via click chemistry. This labeling allowed for the determination of multiple distances of the membrane-bound Ras-dimer measured by fluorescence and electron paramagnetic resonance spectroscopy. In combination with protein-protein docking and biomolecular simulations we identified key residues for dimerization. Site‑directed mutations of these residues prevent dimer formation in our experiments, proving our dimer model to be correct. The presented dimer structure enables now computational drug-screening studies exploiting the Ras dimer interface as alternative drug target.
- 17 February 2021
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessThe Ras Dimer Structure
Oncogenic mutated Ras is a key player in cancer, but despite intense and expensive approaches its catalytic center seems undruggable. The Ras dimer interface is a possible alternative drug target. Dimerization at the membrane affects cell growth signal transduction. In vivo studies indicate that preventing dimerization of oncogenic mutated Ras inhibits uncontrolled cell growth. Conventional computational drug-screening approaches require a precise atomic dimer model as input to successfully access drug candidates. However, the proposed dimer structural models are controversial. Here, we provide a clear-cut experimentally validated N-Ras dimer structural model. We incorporated unnatural amino acids into Ras to enable the binding of labels at multiple positions via click chemistry. This labeling allowed for the determination of multiple distances of the membrane-bound Ras-dimer measured by fluorescence and electron paramagnetic resonance spectroscopy. In combination with protein-protein docking and biomolecular simulations we identified key residues for dimerization. Site‑directed mutations of these residues prevent dimer formation in our experiments, proving our dimer model to be correct. The presented dimer structure enables now computational drug-screening studies exploiting the Ras dimer interface as alternative drug target.
- Open Access
- 3 July 2018
- Published by Wiley in Angewandte Chemie
- Vol. 130 (31) , 10103-10108
Zeitaufgelöst und markerfrei gemessene ligandeninduzierte Konformationsänderungen von HSP90 – hin zu einem Konformationsaktivitätsscreening für die Wirkstoffentwicklung
Während der frühen Medikamentenentwicklung ist die Untersuchung der Protein‐Liganden‐Wechselwirkungen von entscheidender Bedeutung. Die ATR‐FTIR‐Spektroskopie kann Protein‐Liganden‐Wechselwirkungen markerfrei mit hoher räumlicher und zeitlicher Auflösung detektieren. Wir haben das Hitzeschockprotein HSP90, einen wichtigen molekularen Angriffspunkt für Medikamente, auf einem ATR‐Kristall immobilisiert und mit unserem neuartigen Ansatz eine ligandeninduzierte Sekundärstrukturänderung untersucht. Zwei spezifische Bindungsmodi von 19 Inhibitoren wurden analysiert. Unterschiedliche Bindungsmodi können zu unterschiedlicher Wirksamkeit und Spezifität verschiedener Medikamente führen. Darüber hinaus wurden die kobs‐Werte der Dissoziation der Liganden ermittelt. Die Ergebnisse werden durch Röntgenkristallographie für die Strukturänderung und SPR‐Experimente für die Dissoziationskinetik validiert, wobei unsere Methode sämtliche Daten in einem einzigen und einfachen Experiment liefert.
- 3 July 2018
- Published by Wiley in Angewandte Chemie
- Vol. 130 (31) , 10103-10108
Open AccessZeitaufgelöst und markerfrei gemessene ligandeninduzierte Konformationsänderungen von HSP90 – hin zu einem Konformationsaktivitätsscreening für die Wirkstoffentwicklung
Während der frühen Medikamentenentwicklung ist die Untersuchung der Protein‐Liganden‐Wechselwirkungen von entscheidender Bedeutung. Die ATR‐FTIR‐Spektroskopie kann Protein‐Liganden‐Wechselwirkungen markerfrei mit hoher räumlicher und zeitlicher Auflösung detektieren. Wir haben das Hitzeschockprotein HSP90, einen wichtigen molekularen Angriffspunkt für Medikamente, auf einem ATR‐Kristall immobilisiert und mit unserem neuartigen Ansatz eine ligandeninduzierte Sekundärstrukturänderung untersucht. Zwei spezifische Bindungsmodi von 19 Inhibitoren wurden analysiert. Unterschiedliche Bindungsmodi können zu unterschiedlicher Wirksamkeit und Spezifität verschiedener Medikamente führen. Darüber hinaus wurden die kobs‐Werte der Dissoziation der Liganden ermittelt. Die Ergebnisse werden durch Röntgenkristallographie für die Strukturänderung und SPR‐Experimente für die Dissoziationskinetik validiert, wobei unsere Methode sämtliche Daten in einem einzigen und einfachen Experiment liefert.
- Open Access
- 17 May 2018
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 57 (31) , 9955-9960
Ligand‐Induced Conformational Changes in HSP90 Monitored Time Resolved and Label Free—Towards a Conformational Activity Screening for Drug Discovery
Investigation of protein–ligand interactions is crucial during early drug‐discovery processes. ATR‐FTIR spectroscopy can detect label‐free protein–ligand interactions with high spatiotemporal resolution. Here we immobilized, as an example, the heat shock protein HSP90 on an ATR crystal. This protein is an important molecular target for drugs against several diseases including cancer. With our novel approach we investigated a ligand‐induced secondary structural change. Two specific binding modes of 19 drug‐like compounds were analyzed. Different binding modes can lead to different efficacy and specificity of different drugs. In addition, the kobs values of ligand dissociation were obtained. The results were validated by X‐ray crystallography for the structural change and by SPR experiments for the dissociation kinetics, but our method yields all data in a single and simple experiment.
- 17 May 2018
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 57 (31) , 9955-9960
Open AccessLigand‐Induced Conformational Changes in HSP90 Monitored Time Resolved and Label Free—Towards a Conformational Activity Screening for Drug Discovery
Investigation of protein–ligand interactions is crucial during early drug‐discovery processes. ATR‐FTIR spectroscopy can detect label‐free protein–ligand interactions with high spatiotemporal resolution. Here we immobilized, as an example, the heat shock protein HSP90 on an ATR crystal. This protein is an important molecular target for drugs against several diseases including cancer. With our novel approach we investigated a ligand‐induced secondary structural change. Two specific binding modes of 19 drug‐like compounds were analyzed. Different binding modes can lead to different efficacy and specificity of different drugs. In addition, the kobs values of ligand dissociation were obtained. The results were validated by X‐ray crystallography for the structural change and by SPR experiments for the dissociation kinetics, but our method yields all data in a single and simple experiment.
- 18 April 2018
- Published by Royal Society of Chemistry (RSC) in The Analyst
- Vol. 143 (10) , 2276-2284
Highly stable protein immobilization via maleimido-thiol chemistry to monitor enzymatic activity
Immobilizing enzymes for biocatalysis offers many advantages, including easy separation of the enzyme from the product and repeated and continuous use. ATR-FTIR spectroscopy is a versatile tool to monitor immobilized enzymes and has been applied to many proteins. However, while the common and convenient immobilization via oligohistidine on mono-NTA layers is adequate for the measurement of difference spectra induced by ligand binding or photochemistry, it lacks the long term stability that is necessary for monitoring biocatalysis. Here, we report a new immobilization methodology based on maleimido-thiol chemistry. A 12-mercaptododecanoic acid NHS ester monolayer is reacted with 1-(2-aminoethyl)-maleimide to build a thiol reactive surface. Subsequently, NTA-C16-thiol is covalently attached and finally oligohistidine tagged enzymes were immobilized to this surface, which remained bound with a five times higher EC50-value compared to typical mono-NTA layers. To demonstrate the high potential of the surface we analysed decarboxylation reactions catalyzed by arylmalonate decarboxylase. With ATR-FTIR both the enzyme and its substrate conversion can be monitored label free. Correct folding of the enzyme can be evaluated based on the amide band of the immobilized enzyme. In addition, the infrared absorption spectra of educt and product are monitored in real time. We show that hybrid hard–soft multivariate curve resolution improves separation of the product and educt spectra from other effects during the experiments, leading to clean kinetic traces and reaction rates for the catalytic process. Our approach can in principle be extended to any enzyme and is ideally suited for the development of biocatalysts.
- 18 April 2018
- Published by Royal Society of Chemistry (RSC) in The Analyst
- Vol. 143 (10) , 2276-2284
Highly stable protein immobilization via maleimido-thiol chemistry to monitor enzymatic activity
Immobilizing enzymes for biocatalysis offers many advantages, including easy separation of the enzyme from the product and repeated and continuous use. ATR-FTIR spectroscopy is a versatile tool to monitor immobilized enzymes and has been applied to many proteins. However, while the common and convenient immobilization via oligohistidine on mono-NTA layers is adequate for the measurement of difference spectra induced by ligand binding or photochemistry, it lacks the long term stability that is necessary for monitoring biocatalysis. Here, we report a new immobilization methodology based on maleimido-thiol chemistry. A 12-mercaptododecanoic acid NHS ester monolayer is reacted with 1-(2-aminoethyl)-maleimide to build a thiol reactive surface. Subsequently, NTA-C16-thiol is covalently attached and finally oligohistidine tagged enzymes were immobilized to this surface, which remained bound with a five times higher EC50-value compared to typical mono-NTA layers. To demonstrate the high potential of the surface we analysed decarboxylation reactions catalyzed by arylmalonate decarboxylase. With ATR-FTIR both the enzyme and its substrate conversion can be monitored label free. Correct folding of the enzyme can be evaluated based on the amide band of the immobilized enzyme. In addition, the infrared absorption spectra of educt and product are monitored in real time. We show that hybrid hard–soft multivariate curve resolution improves separation of the product and educt spectra from other effects during the experiments, leading to clean kinetic traces and reaction rates for the catalytic process. Our approach can in principle be extended to any enzyme and is ideally suited for the development of biocatalysts.
- Open Access
- 27 July 2012
- Published by Wiley in Chemphyschem
- Vol. 13 (11) , 2617
Cover Picture: Surface-Attached Polyhistidine-Tag Proteins Characterized by FTIR Difference Spectroscopy (ChemPhysChem 11/2012)
- 27 July 2012
- Published by Wiley in Chemphyschem
- Vol. 13 (11) , 2617
Open AccessCover Picture: Surface-Attached Polyhistidine-Tag Proteins Characterized by FTIR Difference Spectroscopy (ChemPhysChem 11/2012)